An Immune Suppression-associated EBV-positive Anaplastic Large Cell Lymphoma With a BRAF V600E Mutation

Area of Science:

• Oncology
• Immunology
• Rheumatology

Background:

• Iatrogenic lymphoproliferative disorders are associated with immunosuppressive agents.
• Novel biologics like TNF-α blockers and JAK-inhibitors treat various autoimmune conditions.
• Distinguishing drug-induced vs. autoimmune-related lymphoproliferation is challenging.

Observation:

• A patient with rheumatoid arthritis on JAK-inhibitors developed Epstein-Barr virus-positive anaplastic large cell lymphoma.
• Sequential skin and lung biopsies were analyzed using comprehensive molecular testing.
• The study investigated the link between immunosuppression, autoimmune disease, and lymphoma.

Findings:

• Molecular analysis revealed a driving BRAF V600E mutation in the lymphoma.
• This mutation was identified through fluorescence in situ hybridization, OncoScan microarray, and pyrosequencing.
• The findings provide insights into the pathogenesis of drug-associated lymphomas.

Implications:

• The BRAF V600E mutation suggests potential for targeted therapy in similar cases.
• This case highlights the complex interplay between immunosuppression, autoimmunity, and lymphomagenesis.
• Further research is needed to understand the specific mechanisms involved.